Elacridar is a potent P-glycoprotein (P-gp/ABCG1) and breast cancer resistance protein (BCRP) inhibitor . GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS.